The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer

by Lilian T. Gien, Helen J. Mackay
Published 2010-01-01

Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review

by Adam S. Komorowski, Helen J. MacKay, Rossanna C. Pezo
Published 2020-07-01

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes

by Lisa Vermij, Nanda Horeweg, Alicia Leon-Castillo, Tessa A. Rutten, Linda R. Mileshkin, Helen J. Mackay, Alexandra Leary, Melanie E. Powell, Naveena Singh, Emma J. Crosbie, Vincent T.H.B.M. Smit, Carien L. Creutzberg, Tjalling Bosse
Published 2021-12-01